Pfizer Inc. $PFE Shares Sold by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its position in Pfizer Inc. (NYSE:PFE) by 2.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 34,933,214 shares of the biopharmaceutical company’s stock after selling 1,034,611 shares during the period. Bank of New York Mellon Corp owned about 0.61% of Pfizer worth $890,098,000 at the end of the most recent quarter.

A number of other institutional investors have also recently modified their holdings of the business. Brighton Jones LLC grew its stake in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC raised its position in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the period. GC Wealth Management RIA LLC lifted its holdings in Pfizer by 46.4% during the second quarter. GC Wealth Management RIA LLC now owns 24,012 shares of the biopharmaceutical company’s stock valued at $582,000 after purchasing an additional 7,611 shares in the last quarter. HB Wealth Management LLC grew its position in shares of Pfizer by 16.9% in the second quarter. HB Wealth Management LLC now owns 291,528 shares of the biopharmaceutical company’s stock valued at $7,067,000 after purchasing an additional 42,200 shares during the period. Finally, Trivium Point Advisory LLC increased its stake in shares of Pfizer by 18.0% during the second quarter. Trivium Point Advisory LLC now owns 36,973 shares of the biopharmaceutical company’s stock worth $896,000 after purchasing an additional 5,639 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Cantor Fitzgerald raised its price target on PFE (supportive near-term catalyst that helped shares earlier in the week). Why Is Pfizer Stock Rising Tuesday?
• Positive Sentiment: Some bullish analysts/investors remain confident in Pfizer’s longer-term outlook, arguing recent policy moves don’t change their favorable stance. Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance
• Neutral Sentiment: Profile pieces and analyst roundups (CEO interview, market commentary) provide context but limited immediate price impact. Pfizer’s CEO on leading after a moonshot—and making deals with Trump
• Neutral Sentiment: Market write-ups note recent outperformance vs. the market on specific days, useful for sentiment tracking but not a structural change. Pfizer (PFE) Exceeds Market Returns: Some Facts to Consider
• Negative Sentiment: Zacks Research downgraded Pfizer from “hold” to “strong sell,” which can trigger selling pressure from momentum/quant strategies and affect sentiment. Zacks Downgrade Coverage
• Negative Sentiment: The U.S. Centers for Medicare & Medicaid Services named Pfizer drugs for the next round of Medicare price negotiations — a material policy risk that could pressure revenue for listed products if negotiated prices are reduced. US Medicare names drugs for next price talks
• Negative Sentiment: Earnings preview commentary warns Q4 results may decline versus expectations, raising the risk of a miss or muted guidance that could weigh on the stock. Earnings Preview: Q4 Earnings Expected to Decline
• Negative Sentiment: Competitive risk: early data from Aclaris shows a hair‑loss candidate outperforming Pfizer’s Litfulo in preclinical/early results, a potential headwind for that franchise. Aclaris hair-loss drug shows faster results
• Negative Sentiment: Broader concerns about leverage and underperformance versus peers (Merck, J&J) keep analysts cautious ahead of secular headwinds like waning COVID product demand and an upcoming patent cliff. Pfizer vs. Merck Stock And JNJ

Pfizer Stock Down 2.3%

Shares of NYSE:PFE opened at $25.89 on Thursday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $27.69. The stock has a market cap of $147.17 billion, a P/E ratio of 15.05 and a beta of 0.47. The business has a fifty day moving average of $25.45 and a two-hundred day moving average of $25.01. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The firm had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. On average, research analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be issued a dividend of $0.43 per share. The ex-dividend date is Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.6%. Pfizer’s dividend payout ratio (DPR) is currently 100.00%.

Analysts Set New Price Targets

Several research firms recently issued reports on PFE. Weiss Ratings reiterated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Citigroup initiated coverage on Pfizer in a research report on Tuesday, December 2nd. They issued a “neutral” rating and a $26.00 target price on the stock. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. BMO Capital Markets restated an “outperform” rating on shares of Pfizer in a report on Wednesday, December 10th. Finally, Scotiabank assumed coverage on shares of Pfizer in a report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $28.06.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.